Psybio Therapeutics Corp Stock Performance
| PSYBF Stock | USD 0.0001 0.00 0.00% |
The company holds a Beta of -1.07, which implies a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning PsyBio Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, PsyBio Therapeutics is expected to outperform it slightly. At this point, PsyBio Therapeutics Corp has a negative expected return of -1.63%. Please make sure to check PsyBio Therapeutics' standard deviation, as well as the relationship between the maximum drawdown and day median price , to decide if PsyBio Therapeutics Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days PsyBio Therapeutics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's fundamental drivers remain nearly stable which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 269.7 K | |
| Total Cashflows From Investing Activities | -3.6 M | |
| Free Cash Flow | -6.9 M |
PsyBio |
PsyBio Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.50 in PsyBio Therapeutics Corp on November 2, 2024 and sell it today you would lose (0.49) from holding PsyBio Therapeutics Corp or give up 98.0% of portfolio value over 90 days. PsyBio Therapeutics Corp is currently producing negative expected returns and takes up 12.6517% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than PsyBio, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
PsyBio Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PsyBio Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as PsyBio Therapeutics Corp, and traders can use it to determine the average amount a PsyBio Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1291
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PSYBF |
Estimated Market Risk
| 12.65 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.63 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average PsyBio Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PsyBio Therapeutics by adding PsyBio Therapeutics to a well-diversified portfolio.
PsyBio Therapeutics Fundamentals Growth
PsyBio Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of PsyBio Therapeutics, and PsyBio Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PsyBio Pink Sheet performance.
| Return On Equity | -3.1 | |||
| Return On Asset | -0.98 | |||
| Current Valuation | 3.69 M | |||
| Shares Outstanding | 80.85 M | |||
| Price To Book | 202.42 X | |||
| EBITDA | (10.91 M) | |||
| Cash And Equivalents | 911.83 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 207.81 K | |||
| Debt To Equity | 7.03 % | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (6.95 M) | |||
| Earnings Per Share | (0.09) X | |||
| Total Asset | 4.01 M | |||
About PsyBio Therapeutics Performance
By analyzing PsyBio Therapeutics' fundamental ratios, stakeholders can gain valuable insights into PsyBio Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if PsyBio Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if PsyBio Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
PsyBio Therapeutics Corp., a biotechnology company, focuses on the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. Psybio Therapeautics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about PsyBio Therapeutics Corp performance evaluation
Checking the ongoing alerts about PsyBio Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for PsyBio Therapeutics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PsyBio Therapeutics generated a negative expected return over the last 90 days | |
| PsyBio Therapeutics has high historical volatility and very poor performance | |
| PsyBio Therapeutics has some characteristics of a very speculative penny stock | |
| PsyBio Therapeutics Corp has accumulated 207.81 K in total debt with debt to equity ratio (D/E) of 7.03, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PsyBio Therapeutics Corp has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist PsyBio Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, PsyBio Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PsyBio Therapeutics Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PsyBio to invest in growth at high rates of return. When we think about PsyBio Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (11.02 M) with loss before overhead, payroll, taxes, and interest of (1.56 M). | |
| PsyBio Therapeutics Corp has accumulated about 911.83 K in cash with (6.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 26.0% of PsyBio Therapeutics outstanding shares are owned by corporate insiders |
- Analyzing PsyBio Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PsyBio Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining PsyBio Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PsyBio Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of PsyBio Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PsyBio Therapeutics' pink sheet. These opinions can provide insight into PsyBio Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for PsyBio Pink Sheet analysis
When running PsyBio Therapeutics' price analysis, check to measure PsyBio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PsyBio Therapeutics is operating at the current time. Most of PsyBio Therapeutics' value examination focuses on studying past and present price action to predict the probability of PsyBio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PsyBio Therapeutics' price. Additionally, you may evaluate how the addition of PsyBio Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |